Cleared Traditional

K120443 - NEUTRAL LUER ACTIVATED DEVICE AND EXTEN...

K120443 is the FDA 510(k) clearance for NEUTRAL LUER ACTIVATED DEVICE AND EXTEN... by Baxter Healthcare Corporation - Renal Division. It is a Class 2 General Hospital device (product code FPA) cleared through the Traditional 510(k) pathway after a 98-day FDA review.

K120443 · Baxter Healthcare Corporation - Renal Division · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 2012
Decision
98d
Days
Class 2
Risk

K120443 is an FDA 510(k) clearance for the NEUTRAL LUER ACTIVATED DEVICE AND EXTENSION SETS WITH NEUTRAL LUER ACTIVATED .... Classified as Set, Administration, Intravascular (product code FPA), Class II - Special Controls.

Submitted by Baxter Healthcare Corporation - Renal Division (Mcgaw Park, US). The FDA issued a Cleared decision on May 22, 2012 after a review of 98 days - within the typical 510(k) review window.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5440 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General Hospital review framework, consistent with the majority of Class II 510(k) submissions.

View all Baxter Healthcare Corporation - Renal Division devices

Submission Details

510(k) Number K120443 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 14, 2012
Decision Date May 22, 2012
Days to Decision 98 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
31d faster than avg
Panel avg: 129d · This submission: 98d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code FPA Set, Administration, Intravascular
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5440
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Peers - FPA Set, Administration, Intravascular

All 454
Devices cleared under the same product code (FPA) and FDA review panel - the closest regulatory comparables to K120443.
FLOWEASE [SUBCUTANEOUS] INFUSION SET
K121092 · Baxter Healthcare Corp · Jun 2012
INTERLINK SYSTEM EXTENSION SET WITH CONTROL-A-FLO-REGULATORY CLEARLINK SYSTEM EXTENSION SET WITH CONTROL-A-FLO-REGULATOR
K121634 · Baxter Healthcare Corporation · Jun 2012
PRIMARY SYMBIQ SET, DITAL MICROBORE TUBING, 0.2 MICRON FILTER, NON-DEHP
K121032 · Hospira, Inc. · Jun 2012
LIFESHIELD VISION INFUSION SET WITH PRE-PIERCED RESEAL
K113683 · Hospira, Inc. · Jan 2012
CYTOGUARD(TM) CLOSED LUER CONNECTOR
K112636 · B.Braun Medical, Inc. · Nov 2011
CLEARLINK LUER ACTIVATED VALVE, CLEARLINK SYSTEM NON-DEHP CATHETER EXTENSION SETS
K112893 · Baxter Healthcare Corporation · Oct 2011